Skip to main content
. Author manuscript; available in PMC: 2023 Jan 10.
Published in final edited form as: Nat Med. 2022 Jan 10;28(1):144–153. doi: 10.1038/s41591-021-01600-6

Extended Data Fig. 3. Exploratory analysis of DNA alterations in progression free survival.

Extended Data Fig. 3

PFS in the atezolizumab + enzalutamide vs enzalutamide treatment arms. 325 samples were included for analysis. DNA alteration biomarkers included Androgen Receptor (AR) amplification status, v-ets erythroblastosis virus E26 oncogene homolog (ERG) fusions, alterations of TP53, BRCA2, SPOP, CDK12 (at least a frameshift, nonsense or splice-site alteration) and ATM. In addition, frameshift mutation burden (FSB) was included. FSB was calculated by the number of frameshift mutations divided by length of genome examined. It was reported as the number of frameshift mutations per megabase (mut/Mb). The cutoff of FSB (8.7 mut/Mb) was previously established in prostate cancer. HRs and CIs were calculated using Cox proportional hazards regression model, and P values were calculated using log-rank test. MST refers to median survival time (PFS) in months.